Radius Health, Inc. (NASDAQ:RDUS) released its earnings results on Thursday. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03), Briefing.com reports. The business had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same quarter last year, the firm earned ($1.07) EPS.

RDUS has been the topic of several recent analyst reports. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Cantor Fitzgerald set a $65.00 target price on Radius Health and gave the stock a “buy” rating in a research report on Monday, July 17th. Canaccord Genuity set a $85.00 target price on Radius Health and gave the stock a “buy” rating in a research report on Monday, July 31st. BidaskClub cut Radius Health from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, Maxim Group reiterated a “positive” rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $52.17.

TRADEMARK VIOLATION WARNING: “Radius Health, Inc. (RDUS) Issues Quarterly Earnings Results” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/02/radius-health-inc-rdus-issues-quarterly-earnings-results.html.

In related news, major shareholder Growth N. V. Biotech acquired 60,000 shares of the stock in a transaction that occurred on Wednesday, August 16th. The shares were acquired at an average price of $35.98 per share, for a total transaction of $2,158,800.00. Following the completion of the purchase, the insider now directly owns 5,248,799 shares of the company’s stock, valued at $188,851,788.02. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of the stock in a transaction that occurred on Wednesday, October 25th. The shares were bought at an average price of $32.85 per share, for a total transaction of $1,642,500.00. Following the purchase, the insider now directly owns 5,548,799 shares of the company’s stock, valued at $182,278,047.15. The disclosure for this purchase can be found here. Insiders have purchased 519,100 shares of company stock worth $17,970,882 in the last quarter. Company insiders own 15.00% of the company’s stock.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Earnings History for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.